Clinical Trials Logo
  1. Home
  2. Demyelinating Diseases
  3. NCT00283023
  4. Details
NCT00283023 Clinical Trial

Oligodendrocyte Progenitor Cell Culture From Human Brain

Demyelinating Diseases Clinical Trial

Official title:
Phase 1: Oligodendrocyte Progenitor Cell Culture From Human Brain

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT00283023
Other study ID # RH-CMR-003
Secondary ID RVH-CMR-003 gran
Status Completed
Phase Phase 1
First received
Last updated
Start date December 2007
Est. completion date December 2010

Study information
Verified date October 2020
Source Rajavithi Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Recent developments in the understanding of stem- and progenitor cell differentiation raises hopes that brain damage in chronic neurological diseases may become repaired by systemic or focal transplantation of such cells. Clinical trials of stem- or progenitor cell transplantation in multiple sclerosis are currently premature. The researchers developed a protocol for human oligodendrocyte progenitor cell culture from human brain for the treatment of demyelinating disease.

Description:

Oligodendrocyte progenitor cell line were cultures and will be transplanted into the patient with Multiple sclerosis.

Recruitment information / eligibility
Status Completed
Enrollment 5
Est. completion date December 2010
Est. primary completion date December 2010
Accepts healthy volunteers No
Gender All
Age group 20 Years to 65 Years
Eligibility Inclusion Criteria: - Male or female 20-65 years of age - Informed consent - Has elective craniotomy surgery Exclusion Criteria: - HIV, hepatitis, and other central nervous system (CNS) infections - Dementia, Alzheimer disease, and neurodegenerative disease

Study Design

Related Conditions & MeSH terms

Intervention

Procedure:
• Oligodendrocyte progenitor cell culture/craniotomy
Oligodendrocyte progenitor cell culture protocol of Rajavithi Hospital will be apply

Locations
Country Name City State
Thailand Assistant Professor Subsai Kongsaengdao Bangkok

Sponsors (1)
Lead Sponsor Collaborator
Rajavithi Hospital

Country where clinical trial is conducted

Thailand, 

Outcome
Type Measure Description Time frame Safety issue
Primary Number of oligodendrocyte progenitor cell differentiation one month
See also
  Status Clinical Trial Phase
Recruiting NCT05199363 - Pediatric Patient Experience on a Diagnostic Path N/A
Terminated NCT01963650 - Natural History Study of Children With Metachromatic Leukodystrophy
Recruiting NCT05792176 - Ukulele Playing to Improve Cognition in People With Multiple Sclerosis: A Feasibility Study N/A
Completed NCT04837651 - Humoral and T-Cell Responses to COVID-19 Vaccination in Multiple Sclerosis Patients Treated With Ocrelizumab Treated With Ocrelizumab or Natalizumab
Not yet recruiting NCT06065670 - Assessing Changes in Multi-parametric MRI in Patients With Acute Demyelinating Lesions Taking Clemastine Fumarate as a Myelin Repair Therapy Phase 1/Phase 2
Active, not recruiting NCT03562975 - Upper Extremity Function in Multiple Sclerosis Patients With Advanced Disability Treated With Ocrevus
Completed NCT01056471 - Autologous Mesenchymal Stem Cells From Adipose Tissue in Patients With Secondary Progressive Multiple Sclerosis Phase 1/Phase 2
Recruiting NCT04762342 - Power Training in Older Multiple Sclerosis Patients N/A
Completed NCT00001287 - Intravenous Immunoglobulin (IVIg) for the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Phase 2
Completed NCT03268239 - Contrast-enhanced 3D T1-weighted Gradient-echo Versus Spin-echo 3 Tesla MR Sequences in the Detection of Active Multiple Sclerosis Lesions N/A
Recruiting NCT05605951 - Acute Optic Neuritis Network: an International Study That Invesitages Subjects With a First-ever Episode of Acute Inflammation of the Optic Nerve
Recruiting NCT04539002 - Aerobic Exercise for Remyelination in Multiple Sclerosis Phase 1/Phase 2
Recruiting NCT05834855 - Non-inferiority Study of Rituximab Compared to Ocrelizumab in Relapsing MS Phase 3